X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (28) 28
index medicus (24) 24
cell line, tumor (22) 22
oncology (19) 19
protein kinase inhibitors - pharmacology (17) 17
article (16) 16
mutation (16) 16
animals (15) 15
mice (15) 15
drug resistance (11) 11
gefitinib (10) 10
lung cancer (10) 10
lung neoplasms - drug therapy (10) 10
lung neoplasms - genetics (10) 10
receptor, epidermal growth factor - genetics (10) 10
antineoplastic agents - pharmacology (9) 9
biochemistry & molecular biology (9) 9
cell lung-cancer (9) 9
receptor, epidermal growth factor - antagonists & inhibitors (9) 9
cancer (8) 8
carcinoma, non-small-cell lung - drug therapy (8) 8
cell biology (8) 8
drug resistance, neoplasm (8) 8
growth-factor receptor (8) 8
amplification (7) 7
carcinoma, non-small-cell lung - genetics (7) 7
cell proliferation - drug effects (7) 7
drug resistance, neoplasm - genetics (7) 7
erlotinib (7) 7
female (7) 7
kinases (7) 7
research (7) 7
genetic aspects (6) 6
lung neoplasms - pathology (6) 6
medicine, research & experimental (6) 6
mutations (6) 6
phosphorylation (6) 6
protein kinase inhibitors - chemistry (6) 6
sensitivity (6) 6
signal transduction (6) 6
acquired-resistance (5) 5
carcinoma, non-small-cell lung - pathology (5) 5
disease models, animal (5) 5
epidermal growth factor receptor (5) 5
kinase inhibitors (5) 5
lung cancer, non-small cell (5) 5
lung neoplasms - metabolism (5) 5
mice, transgenic (5) 5
non-small cell lung carcinoma (5) 5
receptor, erbb-2 - genetics (5) 5
respiratory tract diseases (5) 5
tumors (5) 5
1st-line treatment (4) 4
activation (4) 4
antineoplastic agents - chemistry (4) 4
apoptosis (4) 4
binding sites (4) 4
care and treatment (4) 4
cell line (4) 4
chemotherapy (4) 4
drug therapy (4) 4
drug-resistance (4) 4
expression (4) 4
gene fusions (4) 4
kinase inhibitor (4) 4
lung-cancer (4) 4
male (4) 4
mitogen-activated protein kinase 1 - metabolism (4) 4
models, molecular (4) 4
open-label (4) 4
protein binding (4) 4
receptor, epidermal growth factor - metabolism (4) 4
tyrosine kinase (4) 4
acrylamides - pharmacology (3) 3
activating mutations (3) 3
adult (3) 3
alk (3) 3
amino acid substitution (3) 3
antineoplastic agents - therapeutic use (3) 3
apoptosis - drug effects (3) 3
breast neoplasms - pathology (3) 3
carcinoma, non-small-cell lung - enzymology (3) 3
cell division (3) 3
chronic myeloid-leukemia (3) 3
e2f transcription factors (3) 3
e2f1 transcription factor (3) 3
epidermal growth factor (3) 3
gene amplification (3) 3
health aspects (3) 3
inhibitor (3) 3
lung neoplasms - enzymology (3) 3
met amplification (3) 3
mitogen-activated protein kinase 3 - metabolism (3) 3
multidisciplinary sciences (3) 3
mutants (3) 3
neoplasms (3) 3
neoplasms - drug therapy (3) 3
nih 3t3 cells (3) 3
oncogene proteins, fusion - genetics (3) 3
protein kinase inhibitors - therapeutic use (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 05/2016, Volume 534, Issue 7605, pp. 129 - 132
The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small... 
CELL LUNG-CANCER | EGFR KINASE | GROWTH-FACTOR RECEPTOR | TARGETED THERAPIES | GEFITINIB | ACTIVATION | MECHANISM | MULTIDISCIPLINARY SCIENCES | MUTATIONS | AZD9291 | Lung Neoplasms - drug therapy | Drug Resistance, Multiple - drug effects | Protein Conformation - drug effects | ErbB Receptors - genetics | Lung Neoplasms - pathology | Antineoplastic Agents - pharmacology | Benzeneacetamides - pharmacology | Mutant Proteins - antagonists & inhibitors | Disease Models, Animal | Allosteric Regulation - drug effects | Carcinoma, Non-Small-Cell Lung - pathology | Drug Resistance, Multiple - genetics | ErbB Receptors - antagonists & inhibitors | ErbB Receptors - metabolism | Lung Neoplasms - enzymology | Allosteric Site - drug effects | Mutant Proteins - genetics | Cetuximab - pharmacology | Mutant Proteins - metabolism | Drug Synergism | Drug Resistance, Neoplasm - genetics | Animals | ErbB Receptors - chemistry | Mutant Proteins - chemistry | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Protein Multimerization - drug effects | Drug Resistance, Neoplasm - drug effects | Studies | Phosphorylation | Nuclear magnetic resonance--NMR | Epidermal growth factor | Mutation | Kinases | Enzyme kinetics | Tumors
Journal Article
Nature, ISSN 0028-0836, 12/2009, Volume 462, Issue 7276, pp. 1070 - 1074
Journal Article
Nature Medicine, ISSN 1078-8956, 03/2012, Volume 18, Issue 3, pp. 382 - 384
Journal Article
Nature Medicine, ISSN 1078-8956, 11/2013, Volume 19, Issue 11, pp. 1469 - 1472
Journal Article
Nature chemical biology, ISSN 1552-4450, 12/2014, Volume 10, Issue 12, pp. 1006 - 1012
Her3 (also known as ErbB3) belongs to the epidermal growth factor receptor tyrosine kinases and is well credentialed as an anti-cancer target but is thought to... 
ADJUVANT CHEMOTHERAPY | LUNG-CANCER | DOMAIN | PROTEIN | MET AMPLIFICATION | TYROSINE KINASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | SELECTIVE INHIBITORS | EXTENDED 5-SUBSTITUENT | OVARIAN-CANCER | HER2-POSITIVE BREAST-CANCER | Proto-Oncogene Proteins c-met - metabolism | Adenine - chemical synthesis | Receptor, ErbB-2 - genetics | Antineoplastic Agents - chemical synthesis | Humans | Protein Multimerization | Receptor, ErbB-2 - chemistry | Gene Expression Regulation, Neoplastic | Receptor, ErbB-2 - metabolism | Molecular Targeted Therapy | Receptor, ErbB-3 - chemistry | Proteolysis | Adenosine Triphosphate - metabolism | Antineoplastic Agents - pharmacology | Acrylamides - pharmacology | Protein Kinase Inhibitors - chemical synthesis | Catalytic Domain | Adenine - analogs & derivatives | Signal Transduction | Receptor, ErbB-3 - antagonists & inhibitors | Adenine - pharmacology | Cysteine - chemistry | Receptor, ErbB-3 - genetics | Proto-Oncogene Proteins c-met - genetics | Cell Line, Tumor | Hydrophobic and Hydrophilic Interactions | Cell Proliferation - drug effects | Molecular Docking Simulation | Protein Kinase Inhibitors - pharmacology | Adamantane - chemistry | Proto-Oncogene Proteins c-met - chemistry | Adenosine Triphosphate - chemistry | Acrylamides - chemical synthesis | Signal transduction | Cell growth | Phosphorylation | Pharmacology | Epidermal growth factor | Kinases
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2017, Volume 23, Issue 1, pp. 204 - 213
Journal Article
Proceedings of the National Academy of Sciences, ISSN 0027-8424, 11/2014, Volume 111, Issue 45, pp. E4869 - E4877
The human FGF receptors (FGFRs) play critical roles in various human cancers, and several FGFR inhibitors are currently under clinical investigation.... 
Structure-based drug design | Drug discovery | Cancer drug resistance | Kinase inhibitor | structure-based drug design | WILD-TYPE | MULTIDISCIPLINARY SCIENCES | BCR-ABL | GROWTH-FACTOR RECEPTORS | DRUG-RESISTANCE | kinase inhibitor | LUNG-CANCER | GENE FUSIONS | cancer drug resistance | SELECTIVE INHIBITOR | drug discovery | THERAPEUTIC TARGET | FACTOR RECEPTOR 4 | REGULATES PROLIFERATION | Receptor, Fibroblast Growth Factor, Type 4 - chemistry | Receptor, Epidermal Growth Factor - genetics | Receptor, Fibroblast Growth Factor, Type 4 - metabolism | Receptor, Fibroblast Growth Factor, Type 2 - chemistry | Receptor, Fibroblast Growth Factor, Type 2 - metabolism | Humans | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Crystallography, X-Ray | Structure-Activity Relationship | Mutation, Missense | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Protein Kinase Inhibitors - chemistry | Receptor, Epidermal Growth Factor - metabolism | Neoplasms - genetics | Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Receptor, Fibroblast Growth Factor, Type 4 - genetics | Binding Sites | Neoplasms - enzymology | Antineoplastic Agents - chemistry | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Receptor, Epidermal Growth Factor - chemistry | Neoplasms - drug therapy | Drug Resistance, Neoplasm - genetics | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Kinase Inhibitors - pharmacology | Receptor, Fibroblast Growth Factor, Type 1 - chemistry | Neoplasms - pathology | Receptor, Fibroblast Growth Factor, Type 4 - antagonists & inhibitors | Receptor, Fibroblast Growth Factor, Type 2 - genetics | Amino Acid Substitution | Drug Resistance, Neoplasm - drug effects | Biological Sciences | PNAS Plus
Journal Article
Cancer Research, ISSN 0008-5472, 05/2017, Volume 77, Issue 10, pp. 2712 - 2721
Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non-small cell lung cancer (NSCLC) patients with tumors harboring these... 
CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | ONCOLOGY | ADENOCARCINOMAS | RESISTANCE | OPEN-LABEL | MUTATIONS | TUMORS | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Exons | Humans | Middle Aged | Molecular Conformation | Receptor, ErbB-2 - chemistry | Male | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - chemistry | Codon | Adult | Female | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Disease Models, Animal | Lung Neoplasms - genetics | Gene Expression | Models, Molecular | Treatment Outcome | Antineoplastic Agents - chemistry | Receptor, Epidermal Growth Factor - chemistry | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Protein Binding | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Mutagenesis, Insertional | Protein Kinase Inhibitors - pharmacology | Lung Neoplasms - diagnosis | Amino Acid Substitution | Epidermal growth factor receptors | Lung cancer | Insertion | Non-small cell lung carcinoma | Drug resistance | Patients | ErbB-2 protein | Mutants | Sensitivity | Covalence | Inhibitors | Mutation | Tumors | Cancer | human epidermal growth factor receptor 2 | drug resistance | tyrosine kinase inhibitor | exon 20 | Epidermal growth factor receptor
Journal Article
Journal Article
Molecular Oncology, ISSN 1574-7891, 01/2015, Volume 9, Issue 1, pp. 260 - 269
MET targeted therapies are under clinical evaluation for non-small-cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors (TKI) against MET have varying... 
Crizotinib | ARQ 197 | c-MET | Lung cancer | Tivantinib | c‐MET | C-MET | TYROSINE KINASE | TARGETING MET | ANTITUMOR-ACTIVITY | CYTOTOXIC ACTIVITY | EGFR T790M | AMPLIFICATION | ONCOLOGY | RANDOMIZED PHASE-II | COPY NUMBER | PLUS ERLOTINIB | Proto-Oncogene Proteins c-met - metabolism | Lung Neoplasms - drug therapy | Humans | Lung Neoplasms - pathology | Sulfones - pharmacology | Proto-Oncogene Proteins c-akt - genetics | Quinolines - pharmacology | Phosphorylation - genetics | MAP Kinase Signaling System - genetics | Mitogen-Activated Protein Kinase 1 - genetics | Pyrrolidinones - pharmacology | Indoles - pharmacology | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Pyrazoles - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Mitogen-Activated Protein Kinase 3 - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Proto-Oncogene Proteins c-met - genetics | MAP Kinase Signaling System - drug effects | Mitogen-Activated Protein Kinase 3 - metabolism | Cell Line, Tumor | Pyridines - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mitogen-Activated Protein Kinase 1 - metabolism | Proteins | Tyrosine | Prevention | Medical colleges | Care and treatment | Analysis | Oncology, Experimental | Research | Lung cancer, Non-small cell | Cancer | Phosphorylation | Cytotoxicity | AKT protein | Kinases | Cancer therapies | Experiments | c-Met protein | Cell growth | Cell cycle | Drug dosages | Growth factors | Protein-tyrosine kinase | Genotypes | Immunoglobulins | Polymerization | Extracellular signal-regulated kinase | Non-small cell lung carcinoma | Tumor cell lines | Gene amplification | Cell lines | Mutation | Spindles | Apoptosis
Journal Article